Streetbeat News

Price Targets

XRTX

XORTX Therapeutics shares have seen an increase in their trading value following an endorsement from Alliance Global Partners, which maintained a Buy rating and increased the price target for the stock from $9 to $14.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 4:30 pm

IQV

Truist Securities analyst Jailendra Singh has reaffirmed a Buy rating on IQVIA Holdings (IQV) and increased the price target from $240 to $286.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 4:27 pm

COLL

Truist Securities analyst Gregg Gilbert has reaffirmed a Buy rating on Collegium Pharmaceutical (NASDAQ:COLL) and increased the price target from $31 to $37.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 4:26 pm

ACCD

Stifel analyst David Grossman has maintained a Buy rating on Accolade (NASDAQ:ACCD) but has reduced the price target from $17 to $15.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 4:24 pm

MS

B of A Securities analyst Michael Carrier has maintained a Buy rating on Morgan Stanley (NYSE:MS) and increased the price target from $95 to $100.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 4:22 pm

AVY

Truist Securities analyst Michael Roxland has reaffirmed a Buy rating on Avery Dennison (NYSE:AVY) and increased the price target from $209 to $249.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 4:21 pm

BALL

Truist Securities analyst Michael Roxland has maintained a Hold rating on Ball Corporation (NYSE:BALL) and increased the price target from $54 to $60.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 4:20 pm

JPM

B of A Securities analyst Ebrahim Poonawala has maintained a Buy rating on JPMorgan Chase (NYSE:JPM) and increased the price target from $177 to $188.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 4:19 pm

KRUS

Kura Sushi USA, Inc. (NASDAQ:KRUS) is expected to report a narrower loss of 10 cents per share for Q1 2024 compared to a loss of 21 cents per share in the previous year. Revenue is anticipated to increase to $51.65 million from $39.75 million. The company had mixed results in Q4. Shares slightly declined by 0.1% to $73.18. Analysts have recently adjusted their price targets, with Barclays lowering it from $95 to $67, Craig-Hallum raising it from $88 to $108, Stephens & Co. maintaining at $85, and Citigroup initiating coverage with a target of $88.

Portfolio Pulse from Avi Kapoor

January 04, 2024 | 4:19 pm

BERY

Truist Securities analyst Neal Dingmann has reaffirmed a Buy rating on Berry Global Group (NYSE:BERY) and increased the price target from $74 to $82.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 4:18 pm